What is driving the growth of the Bruton’s Tyrosine Kinase (BTK) inhibitors market? The Bruton’s Tyrosine Kinase (BTK) inhibitors market is experiencing significant momentum due to the rising prevalence of hematologic malignancies, particularly mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). In 2024, the market reached a value of USD 10.48 billion, and it is...